I-MAB News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

17.09.24	I-Mab Reports Promising Results From Phase 1 Study Of Givastomig In Gastric Cancer (RTTNews)
15.07.24	I-Mab's CEO Kannan To Resign, Xi-Yong Fu Appointed As Interim CEO; Wei Fu As Chairman (RTTNews)
06.06.24	I-Mab Appoints Dennis As CMO (RTTNews)
05.06.24	I-Mab Inks Partnership With Bristol Myers Squibb To Evaluate Givastomig In Combination Study (RTTNews)
06.11.23	I-Mab Announces Participation at Jefferies and Piper Conferences in November (PR Newswire)
02.11.23	I-Mab:Felzartamab Granted Breakthrough Therapy Designation By FDA For Primary Membranous Nephropathy (RTTNews)
02.11.23	Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) (PR Newswire)
01.11.23	I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023 (PR Newswire)
16.10.23	I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023 (PR Newswire)
10.10.23	I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503 (PR Newswire)
05.09.23	I-Mab Announces Upcoming Participation at September Conferences (PR Newswire)
17.08.23	I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates (PR Newswire)
08.08.23	I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023 (PR Newswire)
05.07.23	I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC (PR Newswire)
22.06.23	I-Mab Names Raj Kannan CEO - Quick Facts (RTTNews)
22.06.23	I-Mab Announces the Appointment of Raj Kannan as CEO (PR Newswire)
25.05.23	I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 (PR Newswire)
01.05.23	I-MAB Filed 2022 Annual Report on Form 20-F (PR Newswire)
26.04.23	I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023 (PR Newswire)
25.04.23	I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon (PR Newswire)
24.04.23	I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China (PR Newswire)
31.03.23	I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 (PR Newswire)
20.03.23	I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023 (PR Newswire)
07.03.23	MSCI ESG Updated I-Mab to "A" Rating (PR Newswire)
03.11.22	I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022 (PR Newswire)
05.10.22	I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022 (PR Newswire)
13.09.22	I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome (PR Newswire)
10.09.22	I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022 (PR Newswire)
06.09.22	I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022 (PR Newswire)
30.08.22	I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022 (PR Newswire)
23.08.22	I-Mab Announces Share Purchase Plans by the Company and the Senior Management (PR Newswire)
19.08.22	I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022 (PR Newswire)
22.07.22	I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China (PR Newswire)
18.07.22	I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022 (PR Newswire)
06.07.22	I-Mab to Host 2022 R&D Day (PR Newswire)
23.06.22	I-Mab Receives Top Rankings in Five Categories by Institutional Investor (PR Newswire)
15.06.22	HIBio To Develop, Commercialize MorphoSys' Felzartamab, And TJ210 Outside Of Greater China (RTTNews)
15.06.22	I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210 (PR Newswire)
31.05.22	I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency (PR Newswire)
26.05.22	I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab (PR Newswire)
19.05.22	I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab (PR Newswire)
05.05.22	I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act (PR Newswire)
28.04.22	I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer (PR Newswire)
31.03.22	I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment (PR Newswire)
30.03.22	IMAB On Watch, GTH Expects 2022 Revenue To Grow 10-20%, PHVS To Report HAE Trial Data In Q4 (RTTNews)
29.03.22	I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021 (PR Newswire)
18.03.22	I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022 (PR Newswire)
15.03.22	I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act (PR Newswire)
09.03.22	I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
03.03.22	I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu I-MAB (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten